by | Oct 2, 2024 | Uncategorized
The timing with which patients with newly diagnosed multiple myeloma began treatment with oral antimyeloma medications varied greatly by age and race, according to retrospective study results.Black individuals and older adults appeared significantly less likely to...
by | Sep 20, 2024 | Uncategorized
The FDA approved isatuximab-irfc in combination with bortezomib, lenalidomide and dexamethasone for treatment of certain adults with multiple myeloma.The indication applies to adults with newly diagnosed disease who are not eligible for autologous stem cell...
by | Sep 20, 2024 | Uncategorized
Source: CureToday articles The Food and Drug Administration has approved Sarclisa as a first-line treatment for patients with multiple myeloma who are ineligible for autologous stem cell transplant. Read More
by | Sep 12, 2024 | Uncategorized
Source: CureToday articles A Darzalex-based regiment improved MRD negativity rates while sustaining MRD negativity compared with VRd in patients with newly diagnosed, transplant-eligible multiple myeloma. Read More
by | Sep 6, 2024 | Uncategorized
Source: CureToday articles Boruzu, an injectable presentation of Velcade, has been approved by the FDA for patients who either have multiple myeloma or mantle cell lymphoma. Read More
by | Sep 4, 2024 | Uncategorized
Source: CureToday articles Three years after the first FDA approval of CAR-T cell therapy, patients with multiple myeloma are starting to see the therapy emerge in earlier lines. Read More
